biostudies-literatureRofo FTorsten S??derbergs StiftelseHj??rnfondenJeanssons StiftelserOlle Engqvist stiftelseMagnus Bergvalls Stiftelse??hl??n-stiftelsenStiftelsen f??r??Strategisk ForskningPetrus och Augusta Hedlunds StiftelseScience for Life Laboratory??ke Wibergs stiftelseVetenskapsr??detAlzheimerfondenVINNOVA2529-2541https://www.ebi.ac.uk/biostudies/studies/S-EPMC8291608biostudies-literatureUnknown12(13)Alzheimer's disease is the most common neurodegenerative disorder characterized by the pathological aggregation of amyloid-β (Aβ) peptide. A potential therapeutic intervention in Alzheimer's disease is to enhance Aβ degradation by increasing the activity of Aβ-degrading enzymes, including neprilysin. The somatostatin (SST) peptide has been identified as an activator of neprilysin. Recently, we demonstrated the ability of a brain-penetrating SST peptide (SST-scFv8D3) to increase neprilysin activity and membrane-bound Aβ42 degradation in the hippocampus of mice overexpressing the Aβ-precursor protein with the Swedish mutation (APPswe). Using LC-MS, we further evaluated the anti-Alzheimer's disease effects of SST-scFv8D3. Following a triple intravenous injection of SST-scFv8D3, the LC-MS analACS chemical neuroscienceWide-Ranging Effects on the Brain Proteome in a Transgenic Mouse Model of Alzheimer's Disease Following Treatment with a Brain-Targeting Somatostatin Peptide.PMC8291608FO2018-02922019-01885RIF14-00782018-039882017-024132018???05501ICA16-00102018???03320Chourlia AHultqvist GRofo FSyvanen SAndren PEJansson ETMetzendorf NGSandbaumhuter FAMorrison JIfalseWide-Ranging Effects on the Brain Proteome in a Transgenic Mouse Model of Alzheimer's Disease Following Treatment with a Brain-Targeting Somatostatin Peptide.Alzheimer's disease is the most common neurodegenerative disorder characterized by the pathological aggregation of amyloid-β (Aβ) peptide. A potential therapeutic intervention in Alzheimer's disease is to enhance Aβ degradation by increasing the activity of Aβ-degrading enzymes, including neprilysin. The somatostatin (SST) peptide has been identified as an activator of neprilysin. Recently, we demonstrated the ability of a brain-penetrating SST peptide (SST-scFv8D3) to increase neprilysin activity and membrane-bound Aβ42 degradation in the hippocampus of mice overexpressing the Aβ-precursor protein with the Swedish mutation (APPswe). Using LC-MS, we further evaluated the anti-Alzheimer's disease effects of SST-scFv8D3. Following a triple intravenous injection of SST-scFv8D3, the LC-MS anal2021-01-01T00:00:00Z2021 Jul2025-04-21T22:34:04.957Z2022-02-10T21:33:58.382ZS-EPMC82916083417011710.1021/acschemneuro.1c00303